Molecular Partners AG (MOLN.SW) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Switzerland · ISIN CH0256379097
Molecular Partners AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.97 m CHF | 0.00 CHF |
| Gross profit | -42.53 m CHF | -2.15 m CHF |
| Operating income | -61.22 m CHF | -55.44 m CHF |
| EBIT | -54.00 m CHF | -55.40 m CHF |
| Net income | -54.04 m CHF | -61.65 m CHF |
| Diluted EPS – continuing operations | -1.59 CHF | -1.65 CHF |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
More stocks
- Amadeus Fire (AAD.DE)
- EXAGEN INC. (XGN)
- Taiwan Fructose Co Ltd (4207.TWO)
- Pinnacle Bank (PBNK)
- CareCloud, Inc. (CCLD)
- Mcrae Inds Cl A (MCRAA)
- PIE Co., LTD. (452450.KQ)
- Alfa Holdings S.A (RPAD3.SA)
- Serrano 61 Desarrollo SOCIMI SA (YSRR.MC)
- Feng Ching Metal (2061.TWO)
- Western Forest Products Inc (WEF.TO)
- Asia Pacific Satellite Inc (211270.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.